Artificial Neural Network-Based Optimization of Curcumin–Berberine Co-Loaded Nanostructured Lipid Carriers for Biofilm-Associated Diabetic Foot Infections

Artificial Neural Network-Based Optimization of Curcumin–Berberine Co-Loaded Nanostructured Lipid Carriers for Biofilm-Associated Diabetic Foot Infections.

Presentation Outline. Introduction to Diabetic Foot Infections (DFIs) Biofilm-Associated Diabetic Foot Infections Problem Statement Current Therapies in the Management of Diabetic Foot Infections Limitations of Current Therapies Proposed Solution Curcumin, Berberine for Biofilm Disruption Nanostructured Lipid Carriers (NLCs) as the Delivery System for Phytoconstituents Artificial Intelligence (AI) in Formulation Development.

Cont.. Artificial Neural Network (ANN) for Formulation Optimization Innovation & Uniqueness of the Proposed Research Business Model Budget Plan & Justification Conclusion References.

Introduction. Diabetic Foot Infection is a serious complication of diabetes caused by poor wound healing, neuropathy, and reduced blood supply. Once bacteria enter the wound, they form biofilms that protect them from antibiotics and the immune system. This makes treatment difficult and increases the risk of chronic infection and amputation. Therefore, innovative therapies such as nanostructured lipid carriers are needed. Diabetic Foot Infections (DFIs) are infections that develop in foot ulcers of people with diabetes mellitus. They usually occur due to high blood glucose levels, nerve damage (neuropathy), and poor blood circulation, which delay wound healing. Bacteria invade the wound, often forming biofilms, making the infection persistent and difficult to treat..

Biofilm-Associated Diabetic Foot Infection. A biofilm is a structured community of bacteria enclosed within a self-produced extracellular polymeric substance (EPS) matrix. In diabetic foot ulcers, bacteria attach to the wound surface and form biofilms, making the infection chronic and difficult to eradicate. Why is Biofilm a Major Challenge? Protects bacteria from antibiotics and the host immune system. Delays wound healing and promotes persistent infection. Increases antimicrobial resistance (AMR), leading to repeated treatment failure. Responsible for most chronic diabetic foot infections, increasing the risk of hospitalization and amputation. In diabetic foot infections, bacteria do not exist as free-floating cells. Instead, they organize into biofilms, where they are surrounded by a protective EPS matrix. This barrier prevents antibiotics and immune cells from reaching the bacteria effectively, resulting in persistent infections, delayed wound healing, and increased antimicrobial resistance. Therefore, disrupting the biofilm is a key strategy for successful treatment..

Problem Statement. Diabetic Foot Infections (DFIs) remain one of the most serious complications of diabetes, causing prolonged hospitalization, disability, and lower-limb amputation. According to the World Health Organization (WHO), the number of people living with diabetes has increased from 200 million (1990) to 830 million (2022), greatly increasing the burden of diabetic foot complications. In diabetic foot ulcers, biofilms protect bacteria from antibiotics and the immune system, resulting in persistent infection, delayed wound healing, and antimicrobial resistance (AMR). Conventional antibiotic therapy often shows poor penetration into biofilms, requiring prolonged treatment and increasing the risk of treatment failure and recurrence. Therefore, there is an urgent need for an advanced, biofilm-targeted drug delivery system capable of improving antimicrobial efficacy and accelerating wound healing..

Current Therapies in the Management of Diabetic Foot Infections Therapy Examples Purpose Antibiotic Therapy Amoxicillin–Clavulanate, Piperacillin–Tazobactam, Vancomycin, Linezolid Eliminate bacterial infection Wound Debridement Surgical, Mechanical, Enzymatic debridement Remove necrotic tissue and reduce bacterial load Wound Dressings Hydrogel, Alginate, Silver dressings Maintain a moist environment and support healing Off-loading Devices Total Contact Cast (TCC), Therapeutic footwear Reduce pressure on the ulcer and promote healing Surgical Intervention Drainage, Debridement, Amputation Treat severe infection and preserve viable tissue.

Problems with Current Therapies. Current therapies effectively manage infection but fail to completely eradicate biofilms, highlighting the need for advanced biofilm-targeted drug delivery systems. Problems with Current Therapies: Poor antibiotic penetration through the protective biofilm (EPS) matrix. Antimicrobial resistance (AMR) reduces the effectiveness of conventional antibiotics. Persistent biofilm causes chronic infection and frequent recurrence. Slow wound healing due to prolonged inflammation and poor vascularization. Repeated antibiotic use increases adverse effects and the emergence of multidrug-resistant bacteria. Severe cases may require hospitalization and lower-limb amputation..

Problem Solution. To address the shortcomings of current therapies, we propose an ANN-optimized Curcumin–Berberine co-loaded Nanostructured Lipid Carrier system. Curcumin and berberine provide complementary antimicrobial, anti-inflammatory, antioxidant, and anti-biofilm effects. The ANN model will optimize formulation variables to produce stable NLCs with efficient drug loading and controlled release. This targeted nanocarrier is expected to improve biofilm disruption, enhance antibacterial efficacy, promote faster wound healing, and reduce recurrence in diabetic foot infections. Key Features Curcumin + Berberine co-loaded into Nanostructured Lipid Carriers (NLCs) for synergistic antimicrobial and anti-biofilm activity. Artificial Neural Network (ANN) will optimize the formulation to achieve the best particle size, drug loading, stability, and sustained drug release. Targeted delivery improves drug penetration through the biofilm matrix and increases local drug concentration at the infected wound. Sustained release minimizes frequent dosing and enhances therapeutic efficacy. Expected to disrupt biofilms, reduce antimicrobial resistance (AMR), accelerate wound healing, and lower the risk of recurrence and amputation..

Curcumin & Berberine for Biofilm Disruption. Curcumin: A Natural Anti-Biofilm Agent Curcumin is a natural polyphenolic compound obtained from the rhizome of turmeric (Curcuma longa). It possesses antibacterial, anti-biofilm, anti-inflammatory, antioxidant, and wound-healing properties. However, its clinical application is limited by poor water solubility, low bioavailability, and rapid degradation, making nanocarrier-based delivery essential..

Berberine: A Natural Antimicrobial Agent Berberine is a plant-derived isoquinoline alkaloid found in Berberis species. It exhibits broad-spectrum antibacterial, anti-biofilm, anti-inflammatory, and antioxidant activities. Berberine is effective against several multidrug-resistant bacteria commonly associated with diabetic foot infections..

Mechanism of Curcumin & Berberine. CURCUMIN (From Turmeric) Mechanism of Action (Anti—biofilm Activity) I. Inhibits Quorum Sensing (QS) Downregulates QS signals (AHL A1 —2 systems) 2. Reduces EPS Production Suppresses synthesis Of extracellular polymeric substances (EPS) 3. Prevents Bacterial Adhesion Reduces initial attachment Of bacteria to surfaces 4. Inhibits Biofilm Formation and Maturation Disrupts biofilm architecture and bacterial aggregation 5. Disrupts Established Biofilm penetrates biofilm matrix and causes bacterial cell damage 6. Enhances Antibiotic Susceptibility Increases penetration and efficacy Of conventional antibiotics Outcorne Biofilm Disruption Reduced Infection —+ Enhanced Wound Healing BERBERINE (From Berberis species) Mechanism Of Action (Anti—biofilm Activity) 1 . Disrupts Bacterial Cell Membrane Increases membrane permeability and causes leakage of cellular contents Inhibits Quorum Sensing (QS) 2. Blocks QS signaling and communication between bacteria Inhibits EPS Synthesis 3. Downregulates genes responsible for EPS production prevents Bacterial Adhesion 4. Reduces attachment Of bacteria to host tissues and surfaces 5. Destabilizes Biofilm Structure Weakens biofilm integrity and promotes biofilm disassembly 6. Potentiates Antibiotic Activity Reverses resistance and improves bactericidal effect Of antibiotics Outcome Biofilm Eradication —+ Infection Control Irnproved Wound Healing.

Nanostructured Lipid Carriers (NLCs) as the Delivery System for Phytoconstituents.

How NLCs works: Curcumin + Berberine ⬇ Encapsulation into NLCs ⬇ Protection from degradation ⬇ Enhanced penetration through biofilm & infected tissue ⬇ Controlled drug release ⬇ Improved antimicrobial activity + Faster wound healing.

AI in formulation development. A1 IN FORMULATION DEVELOPMENT Using Artificial Intelligence (ANN) to design and optimize Curcumin—Berberine NLCs WHAT IS IT? Artificial Intelligence (A1) uses machine learning algorithms to learn from experimental data, find patterns and predict the best formulation with desired quality attributes. WHY A1? Reduces number of experiments Saves time, cost and resources Improves accuracy and reliability Finds the best combination of ingredients Handles complex relationships between variables and responses EXAMPLE For Curcumin—Berberine NLCS, many factors affect the quality Of nanoparticles. Without A1: We may need to prepare and test 30—50 formulations to get the best one. With A1 (ANN): By training the model with initial experimental data (e.g., 15—20 runs), ANN predicts the optimum formulation with high accuracy. REAL-LIFE IMPACT formulation leads to faster development of effective. stable and safe nanomedicines for biofilm—assoc iated infections. A1-BASED FORMULATION DEVELOPMENT WORKFLOW DEFINE GOAL & INPUT VARIABLES Define the target product profile (T pp) Select formulation and process variables Examples Of Input Variables • Solid lipid type • Liquid lipid type • Surfactant type & conc. • Co-surfactant conc. • Drug (Curcumin & Berberine) conc. • Lipid : Surfactant ratio • Homogenization speed • Sonication time • Temperature DESIGN EXPERIMENTS & COLLECT DATA Perform designed experi ments (DOE) Measure responses (quality attributes) Examples Of Responses • Particle size (nm) • Polydispersity index (PDD • Zeta potential (mV) • Drug entrapment • In vitro drug release (%) • Stability TRAIN A1 MODEL (ANN) The ANN learns the relationship between input variables and EXPERIMENTAL VALIDATION prepare forrnulation and vaEdate results PREDICT & OPTIMIZE ANN predicts the best combination of variables that give the desired responses OPTIMIZED FORMULATION Best Curcumin— Berberine NLC formulation With optimum quality attributes FINAL OUTCOME Stable, effective biofilm-disrupting Curcumin—Berberine NLCs for better antimicrobial therapy and faster wound A1 (ANN) acts like a smart tool that learns from data and helps us find the best formulation quickly and accurately. It reduces experiments and speeds up the development Of high—quality nanomedicines..

Artificial Neural Network (ANN) for Formulation Optimization.

How ANN Optimizes the NLC Formulation A Smart, Faster and Accurate Approach Define Input Variables • Solid lipid type & conc. • Liquid lipid type & Conc. • Surfactant type & conc. • Curcumin conc. • Berberine conc. • Process parameters (homogenization speed, time, temperature) (Q Example: Prepare Initial NLC Formulations • Prepare small set Of formulations (e.g„ 15—20 runs) • Measure quality attributes Generate Experimental Data • Particle size • Entrapment efficiency • Drug release • Zeta potential • Stability Layer Train ANN Model Hidden Layers (learning brain) Output Layer ANN learns the relationship between input variables and formulation responses A1-Guided Feedback for Further Improvement Why ANN for NLC Optimization? Instead of testing 50—100 formulations manually, ANN learns from just a few initial experiments and predicts the Predict & Optimize • Predicts the best combination of formulation variables • Finds the optimum point for desired Free Cwcumin & t Solubility Validate Optimized Formulation e Prepare predicted formulation e Confirm results experimentally e Compare accuracy with ANN prediction Result ANN-Optimized NLCS Obtain Optimized NLC Formulation Optimal particle size High drug loading release Stable formulation Erhanced biofilm Womd best formulation. Input Variables (Example) solid lipid = 4% Liquid lipid = 2% Surfactant 1.5% Curcumin = 2% Berberine = 1% ANN Output (Optirnized NLC) Particle size —i 150 nm Entrapment efficiency 91 % Drug release —i 24 h Stable and uniform NLC High biofilm penetration Reduces trial-and-error experiments Saves time, cost and materials Improves accuracy and reproducibility Optimizes multiple variables at once Provides robust and high-quality formulation t Penetration t activity t tealing.

Innovation & Uniqueness. Why is this Research Innovative? AI-Based Smart Formulation Uses Artificial Neural Network (ANN) to identify the optimum NLC formulation. Reduces trial-and-error experiments, time, and research cost. Novel Combination Therapy Co-delivery of Curcumin + Berberine in a single NLC. Expected to provide synergistic antimicrobial and anti-biofilm activity. Advanced Nanocarrier System Nanostructured Lipid Carriers (NLCs) improve the solubility, stability, and controlled release of phytoconstituents. Enhances drug penetration into the infected wound..

Cont.. Biofilm-Targeted Drug Delivery Directly targets bacterial biofilms, the main cause of chronic diabetic foot infections. Improves local drug concentration and treatment efficacy. Multi-Target Therapeutic Approach A single formulation is designed to: Disrupt biofilms Combat antimicrobial resistance (AMR) Reduce inflammation Accelerate wound healing.

INNOVATION & UNIQUENESS Conventional Therapy vs. Proposed Research Aspect Therapeutic Approach Target Antimicrobial Resistance Drug Delivery System Optimization Strategy Clinical Outcome Overall Impact Conventional Therapy Single antibiotics or synthetic drugs used empirically. Primarily targets planktonic bacteria; limited effect on biofilms. High risk of resistance development and recurrence. Conventional formulations with poor stability, solubility and bioavailability. Trial-and-error method; time-consuming and resource intensive. Incomplete healing, high recurrence and possible amputation. Limited effectiveness; higher treatment cost and hospitalization. Proposed Research Co-delivery of Curcumin & Berberine for synergistic antimicrobial and anti-biofilm action. Specifically targets and disrupts bacterial biofilms. Multi-target action reduces risk of resistance and recurrence. Nanostructured Lipid Carriers (NLCs) improve stability, solubility, and controlled release. Artificial Neural Network (ANN)-based optimization for efficient, accurate and predictive formulation. Enhanced wound healing, reduced infection recurrence and better patient outcomes. Smart, natural, targeted and cost-effective therapy with better translational potential. Key Innovation: Integration of Phytochemicals + Nanotechnology + Artificial Intelligence to develop a next-generation therapy for biofilm-associated diabetic foot infections..

Business Model. 💼 Business Model 👥 Target Customers 🏭 Pharmaceutical Companies 🧴 Cosmeceutical Industry 🏥 Dermatology Clinics & Hospitals 🔬 Research Organizations 💰 Commercial Potential 📜 Patent Filing 🤝 Technology Transfer 🚀 Startup Development.

BUSINESS MODEL A1—Optimized Curcumin—Berberine NLCs for Biofilm—Associated Diabetic Foot Infections From Innovative Research to Affordable & Effective Therapy 1. VALUE PROPOSITION • First A1-optimized Curcumin— Berberine co—loaded N LCS • Potent anti—biofilrn. antimicrobial and anti-inflammatory • Enhances wound healing and reduces • Natural. safe and biocompatible formulati on Smart. Natural. Targeted. Effective. RESEARCH a DISCOVERY Identify problem & 2. TARGET CUSTOMERS Hospitals & Diabetic Foot Clinics • Wound Care Centers • Dermatologists & Podiatrists • Pharmaceutical D i Stributors • Patients with diabetic foot infections Patients at the center Of o r i nnovation A1-BASED OPTIMIZATION (ANN) Optimize formulation With minimal experiments using A NN 7. REVENUE STREAMS 3. KEY PARTNERS • Research Institutions & Universities • Hospitals & Clinical Research Centers • Contract Man Organizations (C MOS) • Raw Material Suppliers • Regulatory & IP Consultants • Technology Transfer Partners Col laborating for innovation and impact 4. KEY ACTIVITIES • A1-based formulation Opti • NLC development & scale—up • Preclinical & clinical evaluation • Quality control & safety Studies • Regulatory approval & IP protection • Manufacturing & product commercialization Research Develop Validate Deliver SCALE-UP & Scale—up p 5. KEY RESOURCES • A1 & Computational n frastructure • Advanced N a logy Laboratory • Skilled Research Formulation & Technolo • Strong Intellectual Property (IP) ail VALUE DELIVERY CHAIN PRECLINICAL & CLINICAL EVALUATION Evaluate safety. efficacy and biofilm disruption potentia Collaborations & exports Technology Talent z Competitive Advantage REGULATORY APPROVAL Obtain approva With quality & Consistency Of life for patients 8. SOCIAL & ECONOMIC IMPACT Sale of NLC forrnulation (Topical product) Hospital & clinic supply ag reements Our Licensing & technology funding Reduces infection recurrence a nd amputa tion risk therapy with high clinical impact 6. CUSTOMER RELATIONSHIP • Evidence-based results & Clinical Outcomes • Continuous engagement with healthcare • Patient awareness & education Long -term collaboration with hospitals & clinics Building trust through results and relationships MARKET LAUNCH & COMMERCIALIZATION ea affordable & effective to pati ents I potential for biofilm— nanomedicines business rnodel bridges INNOVATION and IMPACT to deliver a NEXT-GENERATION THERAPY that is EFFECTIVE, AFFORDABLE and ACCESSIBLE to every patient in need..

Budget Plan & Justification. Total Proposed Budget: ₹1.50 Lakh.